ARP Rheumatology

🧬 Understanding vascular complications in Behçet’s disease

Behçet’s disease can sometimes affect blood vessels, leading to serious complications. This study looked at how often this happens and who is most at risk.

📊 What did they find?
• About 15% of patients developed vascular involvement
• Most cases affected veins, especially:
– Deep vein thrombosis
– Superficial thrombophlebitis
• Some patients also developed arterial problems like aneurysms
• Many had recurrent or multiple vessel involvement

⚠️ Who is at higher risk?
• Men
• Patients whose disease started with eye involvement

💡 Why is this important?
Recognizing these risk factors early can help doctors monitor patients more closely and potentially prevent serious complications.

🔗https://www.arprheumatology.com/article_abstract.php?id=1630

🧬 When cancer immunotherapy causes “Sjögren-like” symptoms… but it’s not Sjögren’s

Treatments like pembrolizumab (used for cancers such as melanoma) can sometimes trigger immune-related side effects that resemble autoimmune diseases.

This case describes a patient who developed:
• Dry mouth and dry eyes
• Salivary gland swelling
• Joint pain

➡️ At first glance, it looked like Sjögren’s disease—but deeper testing showed a different mechanism, driven mainly by T cells rather than the typical antibody pattern.

💡 Why is this important?
Because the condition can be treated effectively without stopping cancer therapy, which is crucial for patient outcomes.

✔️ Symptoms improved with anti-inflammatory treatment (glucocorticoids + hydroxychloroquine)
✔️ Immunotherapy could be continued with careful monitoring

👩‍⚕️ This highlights the need for collaboration between oncologists and rheumatologists to ensure both cancer control and quality of life.

🔗https://www.arprheumatology.com/article_abstract.php?id=1639

🧬 New study: Validation of SLE-DAS in systemic lupus erythematosus (SLE)

Assessing disease activity accurately is key to improving outcomes in people living with lupus. This study evaluated the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in a Russian cohort of 200 patients—and the results are very promising.

🔍 What did they find?
• Strong agreement with existing measures (SLEDAI-2K & Physician Global Assessment)
• High accuracy in identifying active disease (AUC up to 0.97)
• Excellent sensitivity (96%) and specificity (98%)
• Reliable in detecting changes over time

💡 Why does this matter?
SLE-DAS is a continuous, weighted score that may offer a more precise way to monitor lupus activity and support treat-to-target strategies in daily clinical practice.

📊 Overall, this study supports SLE-DAS as a valid and responsive tool that could help clinicians better track disease and guide treatment decisions

🔗https://www.arprheumatology.com/article_abstract.php?id=1641

🚀 Coming Soon: ARP Peer Mentoring Program 2025 🇵🇹

Are you a member of the Portuguese Rheumatology Society interested in improving your scientific peer review skills?

ARP Rheumatology & Sociedade Portuguesa de Reumatologia (SPR) invite you to be part of the first ARP Peer Mentoring Program — a unique opportunity to learn, grow, and connect with leading experts in the field.

✨ What to expect:
🔹 Mentorship from experienced rheumatologists
🔹 Training in scientific peer review
🔹 Exposure to multiple subspecialties
🔹 A chance to strengthen our scientific community

📚 Areas include:
SpA/PsA | Rheumatoid Arthritis | Connective Tissue Diseases | Vasculitis | Paediatric Rheumatology | Epidemiology & Methodology

📢 Applications opening soon — stay tuned!

👉 Follow ARP & SPR for updates and don’t miss your chance to join this exciting initiative